Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices

by Parth Panchal Published on March 07,2017

A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.

• PFE Quick QuotePFENegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• MYL Quick QuoteMYLPositive Net Change

Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M

by Zacks Equity Research Published on March 07,2017

Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.

• SNY Quick QuoteSNYPositive Net Change
• PFE Quick QuotePFENegative Net Change
• VRTX Quick QuoteVRTXPositive Net Change
• CNCE Quick QuoteCNCEPositive Net Change

Trump Tweets, Drug Stocks Tank

by Mark Vickery Published on March 07,2017

???Pricing for the American people will come way down!??? That???s not the only thing: shares of Pfizer (PFE) and Novartis (NOV) fell immediately.

• PFE Quick QuotePFENegative Net Change
• NOV Quick QuoteNOVPositive Net Change
• ADP Quick QuoteADPPositive Net Change
• TWTR Quick QuoteTWTRPositive Net Change

What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

by Zacks Equity Research Published on March 06,2017

Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFENegative Net Change
• BMRN Quick QuoteBMRNNegative Net Change
• MKGAF Quick QuoteMKGAFPositive Net Change

by Zacks Equity Research Published on February 28,2017

• JNJ Quick QuoteJNJPositive Net Change
• PFE Quick QuotePFENegative Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao

by Swarup Gupta Published on February 24,2017

The Dow notched up a record streak of gains over a holiday shortened week.

• YHOO Quick QuoteYHOONo Net Change
• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change

Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

by Arpita Dutt Published on February 24,2017

Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

• AZN Quick QuoteAZNPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFENegative Net Change

Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca

by Zacks Equity Research Published on February 23,2017

Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.

• PFE Quick QuotePFENegative Net Change
• MNTA Quick QuoteMNTAPositive Net Change
• CLVS Quick QuoteCLVSPositive Net Change
• SMMT Quick QuoteSMMTPositive Net Change

Pfizer's Leukemia Candidate Gets Priority Review in U.S.

by Zacks Equity Research Published on February 22,2017

Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.

• PFE Quick QuotePFENegative Net Change
• GSK Quick QuoteGSKPositive Net Change
• EXAS Quick QuoteEXASPositive Net Change
• SNSS Quick QuoteSNSSPositive Net Change

Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

by Zacks Equity Research Published on February 17,2017

Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

by Zacks Equity Research Published on February 15,2017

Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.

• PFE Quick QuotePFENegative Net Change
• LLY Quick QuoteLLYNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change

The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter

by Zacks Equity Research Published on February 14,2017

The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter

• BA Quick QuoteBAPositive Net Change
• PFE Quick QuotePFENegative Net Change
• NVDA Quick QuoteNVDAPositive Net Change

Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%

by Parth Panchal Published on February 13,2017

Pharmaceutical giant Allergan (AGN) announced on Monday they will acquire ZELTIQ Aesthetics (ZLTQ) in a $2.47 billion deal.

• PFE Quick QuotePFENegative Net Change
• AGN Quick QuoteAGNPositive Net Change
• ZLTQ Quick QuoteZLTQNo Net Change

Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

by Zacks Equity Research Published on February 13,2017

The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

• PFE Quick QuotePFENegative Net Change
• LLY Quick QuoteLLYNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• GILD Quick QuoteGILDPositive Net Change

Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs

by Sheraz Mian Published on February 13,2017

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Pfizer (PFE) and Goldman Sachs (GS).

• USB Quick QuoteUSBPositive Net Change
• TWTR Quick QuoteTWTRPositive Net Change
• PFE Quick QuotePFENegative Net Change
• NVDA Quick QuoteNVDAPositive Net Change

Model N (MODN) Q1 Loss Narrower than Expected, Guides Well

by Zacks Equity Research Published on February 07,2017

Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.

• PFE Quick QuotePFENegative Net Change
• NVS Quick QuoteNVSNegative Net Change
• MODN Quick QuoteMODNPositive Net Change
• MIXT Quick QuoteMIXTPositive Net Change

ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

by Zacks Equity Research Published on February 07,2017

ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).

• PFE Quick QuotePFENegative Net Change
• LLY Quick QuoteLLYNegative Net Change
• ENZ Quick QuoteENZPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change

Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)

by Zacks Equity Research Published on February 06,2017

Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.

• AZN Quick QuoteAZNPositive Net Change
• PFE Quick QuotePFENegative Net Change
• MRK Quick QuoteMRKNegative Net Change

Q4 Earnings Faring Well for Pharma ETFs

by Sweta Killa Published on February 06,2017

Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFENegative Net Change
• LLY Quick QuoteLLYNegative Net Change

Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More

by Zacks Equity Research Published on February 06,2017

Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.

• PFE Quick QuotePFENegative Net Change
• LLY Quick QuoteLLYNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• TECH Quick QuoteTECHPositive Net Change

Portola, HealthCare Royalty Partners Ink $150 Million Deal

by Zacks Equity Research Published on February 06,2017

Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.

• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFENegative Net Change
• SCMP Quick QuoteSCMPPositive Net Change
• PTLA Quick QuotePTLAPositive Net Change

Merck???s Keytruda Gets Priority Review for Bladder Cancer

by Zacks Equity Research Published on February 06,2017

Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

• PFE Quick QuotePFENegative Net Change
• GSK Quick QuoteGSKPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Dow 30 Stock Roundup: Apple, Intel, Exxon Beat; Merck, Pfizer, Chevron Miss on Revenues

by Swarup Gupta Published on February 03,2017

The Dow suffered losses over the week as optimism over Trump's election gave way to apprehension over his actions as President.

• PFE Quick QuotePFENegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• AAPL Quick QuoteAAPLPositive Net Change

Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling

by Arpita Dutt Published on February 03,2017

Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).

• SNY Quick QuoteSNYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFENegative Net Change

Agilent (A) Announces Expanded Use of Diagnostic Assay

by Zacks Equity Research Published on February 02,2017

Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 28-8 22C3 pharmDx. This marks the company's effort to expand in the growing companion diagnostics market.

• AZN Quick QuoteAZNPositive Net Change
• PFE Quick QuotePFENegative Net Change
• MRK Quick QuoteMRKNegative Net Change